Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3551
Stabilis Solutions
SLNG
$102M
| $130K | ﹤0.01% |
+24,500
| New | +$177K |
|
|
YARW
3552
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
| $130K | ﹤0.01% |
963
-69
| -7% | -$13.8K |
|
3553
Loop Industries
LOOP
$30.6M
| $129K | ﹤0.01% |
+54,111
| New | +$157K |
|
3554
Mega Matrix
MPU
$13.7M
| $129K | ﹤0.01% |
73,500
-66,526
| -48% | -$126K |
|
|
AUMN
3555
DELISTED
Golden Minerals Company
AUMN
| $129K | ﹤0.01% |
18,829
+5,157
| +38% | +$33.8K |
|
3556
Fusion Fuel Green
HTOO
$17M
| $128K | ﹤0.01% |
826
+220
| +36% | +$34.5K |
|
3557
Lantern Pharma
LTRN
$33.6M
| $127K | ﹤0.01% |
21,100
-200
| -0.9% | -$1K |
|
3558
Sportradar
SRAD
$3.84B
| $127K | ﹤0.01% |
12,800
-24,300
| -65% | -$237K |
|
3559
Monte Rosa Therapeutics
GLUE
$1.36B
| $125K | ﹤0.01% |
+16,400
| New | +$137K |
|
3560
Bank Of The James
BOTJ
$126M
| $124K | ﹤0.01% |
+10,376
| New | +$123K |
|
3561
MoonLake Immunotherapeutics
MLTX
$1.47B
| $122K | ﹤0.01% |
+11,609
| New | +$103K |
|
3562
Cyclerion Therapeutics
CYCN
$18.4M
| $120K | ﹤0.01% |
9,179
-4,990
| -35% | -$59K |
|
|
CDAK
3563
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| $120K | ﹤0.01% |
300,852
+232,552
| +340% | +$153K |
|
3564
US Global Investors
GROW
$38.7M
| $119K | ﹤0.01% |
41,323
+2,008
| +5% | +$5.75K |
|
3565
Holley
HLLY
$362M
| $119K | ﹤0.01% |
56,200
-33,600
| -37% | -$106K |
|
|
AAU
3566
DELISTED
Almaden Minerals Ltd
AAU
| $119K | ﹤0.01% |
+488,823
| New | +$117K |
|
|
WHLM
3567
DELISTED
Wilhelmina International, Inc
WHLM
| $118K | ﹤0.01% |
33,400
-6,612
| -17% | -$25.6K |
|
3568
FinWise Bancorp
FINW
$191M
| $117K | ﹤0.01% |
12,600
+600
| +5% | +$5.5K |
|
3569
Fastly Inc
FSLY
$4.78B
| $117K | ﹤0.01% |
14,300
-1,200
| -8% | -$10.5K |
|
|
LYRA
3570
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $117K | ﹤0.01% |
744
-56
| -7% | -$11.1K |
|
|
SGRP
3571
DELISTED
SPAR Group
SGRP
| $116K | ﹤0.01% |
89,500
+27,500
| +44% | +$40.5K |
|
|
SLAI
3572
DELISTED
SOLAI Ltd ADS
SLAI
| $115K | ﹤0.01% |
10,416
+7,167
| +221% | +$111K |
|
3573
Sidus Space
SIDU
$259M
| $115K | ﹤0.01% |
1,059
+98
| +10% | +$16.6K |
|
|
BBLN
3574
DELISTED
Babylon Holdings Limited
BBLN
| $115K | ﹤0.01% |
17,092
+780
| +5% | +$9.1K |
|
|
GRCL
3575
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $113K | ﹤0.01% |
49,000
-1,300
| -3% | -$3.98K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.